In February 2018, Otsuka changed the Rexulti drug label to include compulsive gambling and other compulsive behaviors as potential side effects of taking the antipsychotic. Rexulti (brexpiprazole) is used to treat schizophrenia and as adjunctive therapy for major depressive disorder. Otsuka now concedes that “post-marketing case reports suggest that patients can experience intense urges, particularly for gambling, and the inability to control these urges while taking Rexulti.” Otsuka is recommending that patients experiencing compulsive gambling and other compulsive behaviors while taking Rexulti should talk to their medical providers immediately about reducing or discontinuing use.
Rexulti is a successor drug to Abilify, another antipsychotic manufactured by Otsuka. Both drugs are chemically similar and work to control the release of dopamine to improve a patient’s state of mind. In 2016, FDA required that a warning be added to the Abilify label to warn of the compulsive behavior side effect. Lawsuits regarding compulsive gambling as a result of taking Abilify are currently proceeding in a Multi-District Litigation before the Honorable M. Casey Rodgers in the Northern District of Florida. GoldenbergLaw Partner Marlene Goldenberg serves on the Plaintiffs’ Steering Committee as the Discovery Liaison.
GoldenbergLaw is currently investigating claims against Rexulti in which an individual experienced compulsive gambling. Contact GoldenbergLaw today for a free consultation.